Related references
Note: Only part of the references are listed.Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study
V. Georgoulias et al.
ANNALS OF ONCOLOGY (2012)
Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients
Brigitte Rack et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2012)
Clinical implications of the detection of circulating tumor cells in breast cancer patients
Malgorzata Banys et al.
BIOMARKERS IN MEDICINE (2012)
Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread
Andreas D. Hartkopf et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study
Marta Pestrin et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Prognostic impact of circulating tumor cells assessed with the CellSearch System (TM) and AdnaTest Breast (TM) in metastatic breast cancer patients: the DETECT study
Volkmar Mueller et al.
BREAST CANCER RESEARCH (2012)
Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse-A European Pooled Analysis
Wolfgang Janni et al.
CLINICAL CANCER RESEARCH (2011)
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial
Tanja Fehm et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial
Sabine Riethdorf et al.
CLINICAL CANCER RESEARCH (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance
Stella Apostolaki et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
A pan-HER approach for cancer therapy: background, current status and future development
Zhongdong Huang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer
Maaike de Boer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
Tanja Fehm et al.
BREAST CANCER RESEARCH (2009)
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow-a long-term follow-up
I. J. Diel et al.
ANNALS OF ONCOLOGY (2008)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Klaus Pantel et al.
NATURE REVIEWS CANCER (2008)
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer
Helga Bernhard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
Tanja Fehm et al.
BREAST CANCER RESEARCH (2008)
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance
Tanja Fehm et al.
BREAST CANCER RESEARCH (2008)
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer
Michail Ignatiadis et al.
CLINICAL BREAST CANCER (2007)
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance
S. Apostolaki et al.
ANNALS OF ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm et al.
BREAST CANCER RESEARCH (2007)
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients
Erich F. Solomayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients
P Wülfing et al.
CLINICAL CANCER RESEARCH (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A pooled analysis of bone marrow micrometastasis in breast cancer
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence
W Janni et al.
CANCER (2005)
Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients
JY Pierga et al.
CLINICAL CANCER RESEARCH (2004)
Circulating tumor cells in patients with breast cancer dormancy
SD Meng et al.
CLINICAL CANCER RESEARCH (2004)
Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer
V Bozionellou et al.
CLINICAL CANCER RESEARCH (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells
A Hemsen et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer
G Wiedswang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
D Gancberg et al.
ANNALS OF ONCOLOGY (2002)
Epithelial cells in bone marrow of breast cancer patients at time of primary surgery:: Clinical outcome during long-term follow-up
G Gebauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report
C Vogel et al.
EUROPEAN JOURNAL OF CANCER (2001)
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
S Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
